PCVX vs RGEN
Vaxcyte, Inc. vs Repligen — AI-powered side-by-side comparison
PCVX
Vaxcyte, Inc.
64
Buy
VS
| Metric | PCVX | RGEN |
|---|
| AI Score |
64
|
60
|
| Price |
$60.48
|
$180.00
|
| P/E Ratio |
-8.00×
|
245.53×
|
| ROE |
-28.5%
|
2.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
51.1%
|
| Debt / Equity |
0.04×
|
0.33×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.8
|
83.2
|
| Beta |
1.21
|
1.012
|
| Expected Upside |
+0.9%
|
+0.0%
|
AI Committee View
Current Innellis committee reasoning for PCVX versus RGEN.
PCVX leads by 4 points.
PCVX scores 64/100 (Buy) versus RGEN at 60/100 (Buy).
PCVX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -37.6% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 21.2% signals elevated volatility — Risk
RGEN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Value Analyst remains cautious — p/e of 227.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 227.0 is expensive by classic value standards — Value
- Price-to-book of 4.4x prices in significant intangible value — Value
- ROE of only 2.0% -- cheap may mean cheap for a reason — Value